Randomized, Open label, Multiple-Dose Study to Evaluate the Pharmacodynamics, Safety and Pharmacokinetics of BMS-663068 in HIV-1 Infected Subjects

Registry ID

EUCTR2009-013657-14

Source registry

EUCTR

Status

Completed

Phase

PHASE2

Sponsor

Bristol-Myers Squibb International Corporation

Start date

2009-11-10

Completion date

2010-06-22

Last update

2026-08-16

Conditions

• HIV-1

Summary

To assess the antiviral activity of BMS-626529 following administration of selected regimens of BMS-663068 with and without Ritonavir (RTV) administered orally to HIV infected subjects for 8 days.

Locations

• , , Germany

Related clinical trials

• Safety and Pharmacokinetics Study of PGT121.414.LS Alone and in Combination With VRC07-523LS in Infants Exposed to HIV-1
• Inhibiting the Anti-apoptotic Factor, BCL-2, at the Time of ART Initiation to Promote Apoptosis of HIV-infected Cells and Restrict the Seeding of the HIV Reservoir (The INITIATE Study)
• CMV-specific HIV-CAR T Cells as Immunotherapy for HIV/AIDS
• Switch to Dolutegravir Plus Lamivudine Dual-Therapy in Transgender Women Living With HIV on Virologically Suppressive Antiretroviral Therapy (TRANS-SWITCH)
• Viral Infection of HSPC Impacts Hematopoiesis

View on source registry